Australia-wide dispatch

Quantified
Peptides
Eloralintide 10mg — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

Peptides

Eloralintide

Eloralintide (LY3841136), a selective amylin receptor agonist. Supplied as a lyophilised powder in 10mg vials.

Supplied as lyophilised powder in a 10mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.

Product information

About Eloralintide

LY3841136

Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.

Eloralintide (LY3841136) is a long-acting, selective amylin receptor agonist developed by Eli Lilly. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells.

It has been studied as a once-weekly compound in metabolic research. The Phase 2 trial, which enrolled 263 adults across research centres in the United States, was presented at ObesityWeek 2025 and published in The Lancet; Phase 3 studies were announced afterwards. A separate Phase 2 study examines it alongside tirzepatide.

Eloralintide is an investigational compound and not an approved medicine. It is supplied here as a reference material for in-vitro research into amylin receptor pharmacology.

Type
Selective, long-acting amylin receptor agonist
Research Areas
Amylin receptor signalling, satiety pathways, weight research
Code Name
LY3841136
Developer
Eli Lilly
Primary Receptor
Amylin receptors (AMY1–3)
Development Stage
Phase 3 (investigational)
Regulatory Status
Not approved
  1. 01Amylin Receptor SelectivityEloralintide is designed to act selectively at amylin receptors, which are formed by the calcitonin receptor together with receptor activity-modifying proteins (RAMPs). Research compares this selectivity with dual amylin and calcitonin receptor agonists.
  2. 02Satiety SignallingAmylin receptor agonists are studied for their action on brainstem and hypothalamic circuits involved in satiety and food intake, a pathway distinct from the GLP-1 receptor.
  3. 03Clinical InvestigationA 48-week randomised, placebo-controlled Phase 2 trial in adults with obesity or overweight was published in The Lancet in 2025. Eloralintide remains investigational and is not approved by any regulator.

References

  1. 1Billings LK et al. Eloralintide, a selective amylin receptor agonist, in adults with obesity or overweight: a randomised, placebo-controlled phase 2 trial. Lancet. 2025.
  2. 2ClinicalTrials.gov: NCT06230523.
  3. 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=eloralintide

Also in this range.

Compounds the supplier files alongside this one.

View the range